Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5

Autophagy

Volumn 9, Issue 1, 2013, Pages 20-32

  Ouyang, Dong Yun ^a   Xu, Li Hui ^a   He, Xian Hui ^a   Zhang, Yan Ting ^a   Zeng, Long Hui ^a   Cai, Ji Ye ^b   Ren, Shuai ^a  

^a JINAN UNIVERSITY   (China)

^b Jina University   (China)

Author keywords

ATG5; Autophagy; DU145 cells; LC3; LNCaP cells; PC 3 cells; Prostate cancer; Valproic acid

Indexed keywords

AUTOPHAGY PROTEIN 16L1; AUTOPHAGY PROTEIN 5; CHLOROQUINE; COMPLEMENTARY DNA; HISTONE DEACETYLASE INHIBITOR; PEPTIDES AND PROTEINS; RAPAMYCIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; EXON; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MACROAUTOPHAGY; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROSTATE CANCER; PROTEIN DEGRADATION; RNA ISOLATION; TRANSIENT EXPRESSION;

EID: 84872178548     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.22397     Document Type: Article

References (51)

1. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008; 3:300-9; PMID:19029799; http://dx.doi.org/10.4161/epi.3.6.7273
2. Zhao X, Yang W, Shi C, Ma W, Liu J, Wang Y, et al. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumour Biol 2011; 32:335-46; PMID:21113745; http://dx.doi.org/10.1007/s13277-010-0126-5
3. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106:112-9; PMID:16323176; http://dx.doi.org/10.1002/cncr. 21552
4. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98:604-10; PMID:18212746; http://dx.doi.org/10. 1038/sj.bjc.6604199
5. Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006; 66:7237-44; PMID:16849572; http://dx.doi.org/10.1158/0008-5472.CAN-05-0487
6. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007; 67:1099-110; PMID:17477369; http://dx.doi.org/10.1002/pros.20587
7. Valentini A, Biancolella M, Amati F, Gravina P, Miano R, Chillemi G, et al. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Drug Metab Dispos 2007; 35:968-72; PMID:17371798; http://dx.doi.org/10.1124/dmd.107.014662
8. Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N. A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 2008; 1:141-7; PMID:18795124
9. Long J, Zhao J, Yan Z, Liu Z, Wang N. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40. Int J Cancer 2009; 124:1235-44; PMID:19058176; http://dx.doi.org/10.1002/ijc.24074
10. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, Sica G. Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol 2008; 32:1293-303; PMID:18497991
11. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36:2503-18; PMID:15325588; http://dx.doi.org/10.1016/j.biocel.2004.05.009
12. Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 2001; 152:657-68; PMID:11266458; http://dx.doi.org/10. 1083/jcb.152.4.657
13. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, Kalkanis SN, et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009; 125:717-22; PMID:19431142; http://dx.doi.org/10.1002/ijc.24402
14. Turner LS, Cheng JC, Beckham TH, Keane TE, Norris JS, Liu X. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis 2011; 14:30-7; PMID:21116286; http://dx.doi.org/10.1038/pcan.2010.47
15. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6:322-9; PMID:20224296; http://dx.doi.org/10.4161/ auto.6.3.11625
16. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110:313-22; PMID:17363733; http://dx.doi.org/10.1182/blood-2006-10-050260
17. Ko H, Kim YJ, Park JS, Park JH, Yang HO. Autophagy inhibition enhances apoptosis induced by ginsenoside Rk1 in hepatocellular carcinoma cells. Biosci Biotechnol Biochem 2009; 73:2183-9; PMID:19809182; http://dx.doi.org/10.1271/ bbb.90250
18. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, et al. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 2010; 1:40-9; PMID:20811583; http://dx.doi.org/10.1177/ 1947601909358324
19. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, et al. Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ 2006; 13:446-53; PMID:16167071; http://dx.doi.org/10.1038/sj.cdd.4401759
20. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010; 12:328-40; PMID:20308311; http://dx.doi.org/10.1093/neuonc/nop005
21. Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 2011; 199:292-302; PMID:22056603; http://dx.doi.org/10.1016/j.neuroscience. 2011.10.031
22. Ouyang D, Zhang Y, Xu L, Li J, Zha Q, He X. Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin (Shanghai) 2011; 43:487-95; PMID:21628505; http://dx.doi.org/10.1093/abbs/gmr032
23. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66:10040-7; PMID:17047067; http://dx.doi.org/10.1158/0008-5472.CAN-06-0802
24. Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J Biol Chem 2007; 282:37298-302; PMID:17986448; http://dx.doi.org/10. 1074/jbc.C700195200
25. Korolchuk VI, Menzies FM, Rubinsztein DC. A novel link between autophagy and the ubiquitin-proteasome system. Autophagy 2009; 5:862-3; PMID:19458478
26. Larsen KB, Lamark T, Øvervatn A, Harneshaug I, Johansen T, Bjørkøy G. A reporter cell system to monitor autophagy based on p62/SQSTM1. Autophagy 2010; 6:784-93; PMID:20574168; http://dx.doi.org/10.4161/ auto.6.6.12510
27. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc.M702824200
28. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7:279-96; PMID:21189453; http://dx.doi.org/10.4161/ auto.7.3.14487
29. Fujita K, Maeda D, Xiao Q, Srinivasula SM. Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation. Proc Natl Acad Sci U S A 2011; 108:1427-32; PMID:21220332; http://dx.doi.org/10.1073/pnas.1014156108
30. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schröder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35:664-71; PMID:10492644; http://dx.doi.org/10.1016/S0959-8049(98)00435-3
31. Fujita N, Itoh T, Omori H, Fukuda M, Noda T, Yoshimori T. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell 2008; 19:2092-100; PMID:18321988; http://dx.doi.org/10. 1091/mbc.E07-12-1257
32. Sou YS, Tanida I, Komatsu M, Ueno T, Kominami E. Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem 2006; 281:3017-24; PMID:16303767; http://dx.doi.org/10.1074/jbc.M505888200
33. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009; 461:654-8; PMID:19794493; http://dx.doi.org/10.1038/nature08455
34. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221:117-24; PMID:20225337; http://dx.doi.org/10.1002/path.2694
35. Vadlamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosine- independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 1996; 271:20235-7; PMID:8702753; http://dx.doi.org/10.1074/jbc.271.34.20235
36. Watanabe Y, Tanaka M. p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate. J Cell Sci 2011; 124:2692-701; PMID:21771882; http://dx.doi.org/10.1242/jcs.081232
37. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24:8055-68; PMID:15340068; http://dx.doi.org/10.1128/MCB.24.18.8055-8068.2004
38. Shvets E, Elazar Z. Autophagy-independent incorporation of GFP-LC3 into protein aggregates is dependent on its interaction with p62/SQSTM1. Autophagy 2008; 4:1054-6; PMID:18776740
39. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14:1815-23; PMID:8114714
40. Schneider E, Montenarh M, Wagner P. Regulation of CAK kinase activity by p53. Oncogene 1998; 17:2733-41; PMID:9840937; http://dx.doi.org/10.1038/sj.onc. 1202504
41. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57:205-25; PMID:14518029; http://dx.doi.org/10.1002/pros.10290
42. Chen X, Wong JY, Wong P, Radany EH. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 2011; 9:448-61; PMID:21303901; http://dx.doi.org/10.1158/1541-7786.MCR-10-0471
43. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011; 39:111-9; PMID:21519790
44. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005; 12:482-91; PMID:15746940; http://dx.doi.org/10.1038/sj.cdd.4401581
45. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006; 191:465-72; PMID:17088416; http://dx.doi.org/10.1677/joe.1.06970
46. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005; 65:3815-22; PMID:15867379; http://dx.doi.org/10.1158/0008-5472. CAN-04-2478
47. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39:596-604; PMID:17435756; http://dx.doi.org/10.1038/ng2032
48. Naser SA, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, et al. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. World J Gastroenterol 2012; 18:412-24; PMID:22346247; http://dx.doi.org/10.3748/wjg.v18.i5.412
49. Plantinga TS, Crisan TO, Oosting M, van de Veerdonk FL, de Jong DJ, Philpott DJ, et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 2011; 60:1229-35; PMID:21406388; http://dx.doi.org/10.1136/gut.2010.228908
50. Plantinga TS, Joosten LA, Netea MG. ATG16L1 polymorphisms are associated with NOD2-induced hyperinflammation. Autophagy 2011; 7:1074-5; PMID:21673517; http://dx.doi.org/10.4161/auto.7.9.15867
51. Ouyang D, He X, Xu L, Wang X, Gao Q, Guo H. Differential cell surface expression of rhesus macaque's major histocompatibility complex class I alleles Mamu-B*1703 and Mamu-B*0101. Acta Biochim Biophys Sin (Shanghai) 2010; 42:281-7; PMID:20383467; http://dx.doi.org/10.1093/abbs/gmq019